“Double expressor” diffuse large B-cell lymphoma: A case report and literature review

Diffuse large B-cell lymphoma, not otherwise specified, is the most common type of non-Hodgkin lymphoma worldwide, accounting for 30-40% all lymphomas. It represents a collection morphologically, genetically and clinically different diseases. Therefore, it can be subdivided into morphological variants, phenotypic subtypes, molecular or genetic categories. More recently, diffuse has witnessed advances in profiling treatment patients with refractory relapsed disease. The optimal management requires integrated immunophenotypic analysis cell tissue, along chromosome analyses. Double-expressor defined as overexpression MYC BCL2 proteins related to underlying chromosomal rearrangements, accounts 20% 30% cases. In latest, 5th edition World Health Organization Classification Hematolymphoid Tumors-lymphoid neoplasms, double-expressor an independent entity, but been proven marker poor outcome lymphoma. However, degree adverse prognosis lesser than double-hit Although feature confirmed prognostic patients, currently no sufficient data available support intensification over standard rituximab, cyclophosphamide, doxorubicin, vincristine prednisone regimen. Well-designed randomized clinical trials are mandatory order properly respond this substantial dispute.